Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...
Financial terms include $650 million upfront, up to $9.85 billion in milestones, and double-digit royalties per approved product, with closing contingent on regulatory approvals in Q3 2026. Portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results